Espicom's generics company reports will help you to understand the dynamic and complex issues affecting the business of leading generic industry players. These informative reports provide an insight into the company, covering the structure of the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation. Egis was established in Budapest, Hungary, in 1913. The company has three manufacturing sites: two in Budapest, and one at Körmend, near the border with Austria.

The company has 18 subsidiaries under its direct control. Six are in Hungary, with the remaining 12 abroad. Additionally, Egis has seven indirect subsidiaries, all of which are in Hungary, and 20 representative offices across the world.

Egis has been listed on the Budapest Stock Exchange since 1994. However, Hungarian investors only make up around 6% of its ownership. The majority owner is the French firm, Servier, which has 51% of Egis' shares. Egis acts as a distributor for Servier in Hungary, and supplies generics to France through Servier's generic subsidiary. It also markets products through Servier's subsidiaries in the United Kingdom.

Outside of Hungary, the company's largest markets are those of Russia and the CIS, and Central and Eastern Europe.